Mitotic slippage and the subsequent cell fates after inhibition of Aurora B during tubulin-binding agent–induced mitotic arrest
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-17002-z
Abstract: Tubulin-binding agents (TBAs) are designed to target microtubule (MT) dynamics, resulting in compromised mitotic spindles and an unsatisfied spindle assembly checkpoint. The activity of Aurora B kinase is indispensable for TBA-induced mitotic arrest, and its… read more here.
Keywords: tubulin binding; slippage; mitotic slippage; cell ... See more keywords
Tubulin‐binding peptide RR‐171 derived from human umbilical cord serum displays antitumor activity against hepatocellular carcinoma via inducing apoptosis and activating the NF‐kappa B pathway
Sign Up to like & getrecommendations! Published in 2022 at "Cell Proliferation"
DOI: 10.1111/cpr.13241
Abstract: Hepatocellular carcinoma (HCC) still presents a high incidence of malignant tumours with poor prognosis. There is an urgent need for new therapeutic agents with high specificity, low toxicity and favourable solubility for the clinical treatment… read more here.
Keywords: hepatocellular carcinoma; 171 derived; binding peptide; peptide 171 ... See more keywords
Tubulin-binding cofactor E-like (TBCEL), the protein product of the mulet gene, is required in the germline for the regulation of inter-flagellar microtubule dynamics during spermatid individualization
Sign Up to like & getrecommendations! Published in 2020 at "Biology Open"
DOI: 10.1242/bio.049080
Abstract: ABSTRACT Individual sperm cells are resolved from a syncytium during late step of spermiogenesis known as individualization, which is accomplished by an Individualization Complex (IC) composed of 64 investment cones. mulet encodes Tubulin-binding cofactor E-like… read more here.
Keywords: individualization; binding cofactor; tubulin binding; tbcel ... See more keywords
Antitumor Activity of Tubulin-Binding Agent MPC-6827 on Different Types of Cancer Cell Lines.
Sign Up to like & getrecommendations! Published in 2022 at "Cellular and molecular biology"
DOI: 10.14715/cmb/2022.68.4.13
Abstract: In this study, the antitumor effects of tubulin-binding agent MPC-6827 on HeLa, MCF-7 and A549 cell lines originated from cervix carcinoma, metastatic breast adenocarcinoma and adenocarcinomic human alveolar basal epithelial cells respectively were determined. Cell… read more here.
Keywords: mpc 6827; index; cell; cell lines ... See more keywords
Selective delivery of clinically approved tubulin binding agents through covalent conjugation to an active targeting moiety.
Sign Up to like & getrecommendations! Published in 2022 at "Current medicinal chemistry"
DOI: 10.2174/0929867329666220401105929
Abstract: The efficacy and tolerability of tubulin binding agents are hampered by their low specificity for cancer cells, like most clinically used anticancer agents. To improve specificity, tubulin binding agents have been covalently conjugated to agents… read more here.
Keywords: clinically approved; delivery clinically; tubulin binding; selective delivery ... See more keywords
Imaging-Guided Evaluation of the Novel Small-Molecule Benzosuberene Tubulin-Binding Agent KGP265 as a Potential Therapeutic Agent for Cancer Treatment
Sign Up to like & getrecommendations! Published in 2021 at "Cancers"
DOI: 10.3390/cancers13194769
Abstract: Simple Summary Vascular-disrupting agents promise significant therapeutic efficacy against solid tumors by selectively damaging tumor-associated vasculature. Dynamic BLI and oxygen-enhanced multispectral optoacoustic tomography (OE-MSOT) were used to compare vascular shutdown following administration of KGP265. BLI… read more here.
Keywords: breast; tubulin binding; growth delay; vascular shutdown ... See more keywords
Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14174208
Abstract: Simple Summary Vascular-disrupting agents promise significant therapeutic efficacy against solid tumors by selectively damaging tumor-associated vasculature. Following administration of the phosphate prodrug OXi6197, dynamic bioluminescence imaging revealed dose-responsive vascular shutdown in MDA-MB-231 human breast tumor… read more here.
Keywords: disrupting activity; prodrug oxi6197; mda 231; vascular disrupting ... See more keywords